Whole Exome Sequencing Market Size, Share, Growth, Demand, Emerging Trends and Forecast by 2029

Whole Exome Sequencing Market report is designed with the scrupulous Market analysis carried out by a team of industry experts, dynamic analysts, skilful forecasters, and well-informed researchers. And not to mention, the report is amazingly characterized by using several charts, graphs, and tables depending on the extent of data and information involved. What is more, influencing factors such as Market drivers, Market restraints, and competitive analysis is studied with the SWOT analysis which is the most established tool when it comes to generate Market research report. Businesses can achieve complete knowhow of general Market conditions and tendencies with the information and data covered in the reliable Whole Exome Sequencing report.

The large scale Whole Exome Sequencing Market report comprises of all the crucial Market parameters and hence it can be used for the business. Furthermore, complete company profiles covered in this report also explains what recent developments, product launches, joint ventures, mergers, and acquisitions are taking place by the numerous key players and brands in the Market. The report is provided with the transparent research studies which have taken place by a team work of experts in their own domain. The world class Whole Exome Sequencing Market research report also endows with company profiles and contact information of the key Market players in the manufacturer’s section.

Global whole exome sequencing market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the market is growing with a CAGR of 19.0% in the forecast period of 2022 to 2029. The increase in healthcare expenditure and funding are the major drivers which propelled the demand of the market in the forecast period.

The major players covered in the Whole Exome Sequencing market report are Thermo Fisher Scientific Inc., QIAGEN, Illumina, Inc., Beckman Coulter, Inc., Eurofins Scientific, BIONEER CORPORATION, ExoDx (a part of Bio-Techne), FOUNDATION MEDICINE, INC. (A subsidiary of F. Hoffmann-La Roche Ltd), GeneFirst Limited, CeGaT GmbH, Meridian, Merck KGaA, SOPHiA GENETICS, Azenta U.S. Inc., CD Genomics, Twist Bioscience, PerkinElmer Genomics (A Subsidiary of PerkinElmer Inc.), GeneDx, LLC, Psomagen, Integrated DNA Technologies, Inc., among others.

Whole Exome Sequencing Market Dynamics

Drivers

• Increase in the adoption of next generation sequencing

As genomics-focused pharmacology continues to play a greater role in the treatment of various chronic diseases especially cancer, next-generation sequencing (NGS) is evolving as a powerful tool for providing a deeper and more precise insight at molecular underpinnings of individual tumours and specific receptors.

NGS offers advantages in accuracy, sensitivity and speed compared to traditional methods that have the potential to make a significant impact on the field of oncology. Because NGS can assess multiple genes in a single assay, the need to order multiple tests to identify the causative mutation is eliminated.

• Growing usage of targeted sequencing methods

As genomics-focused pharmacology continues to play a greater role in the treatment of various chronic diseases especially cancer, next-generation sequencing (NGS) is evolving as a powerful tool for providing a deeper and more precise insight at molecular underpinnings of individual tumours and specific receptors.

NGS offers advantages in accuracy, sensitivity and speed compared to traditional methods that have the potential to make a significant impact on the field of oncology. Because NGS can assess multiple genes in a single assay, the need to order multiple tests to identify the causative mutation is eliminated.

Restraint

• Less comprehensive coverage of exons

All the exons are not comprehensively captured. The exon of importance may not be included in the current standard annotations of the human genome; and it is merely arduous to cover 100% of the exome with the current WES technology. Consequently, disease-causing variants in these "missed" exons go undetected.

WES has low sensitivity for structural variations, hence detection is limited. Nonetheless some CNVs, including indels and duplications, can be detected by WES, the technical limitation implies that others are likely missed

Opportunity

• Strategic Initiatives by the key market player

The demand for whole exome sequencing is increasing in the market owing to the increased incidence of genetic disease along with increased geriatric population across the region. Thus, the top market players have implemented the strategy of collaboration with other market players aimed at improving business operations and profitability.

Challenge

• Ethical and legal issues related to whole exome sequencing

Rapid advances in high throughput genomic technologies and next generation sequencing are making medical genomic research more readily accessible and affordable, including the sequencing of patient and control whole genomes and exomes in order to elucidate genetic factors underlying disease. Progress of high throughput genomic technologies and next generation sequencing (NGS) methods in recent years has changed the scope of human genomic studies. These advances have made it feasible to routinely perform whole exome sequencing studies.

By Geographical Regions:-

• Asia Pacific: China, Japan, India, and Rest of Asia Pacific
• Europe: Germany, the UK, France, and Rest of Europe
• North America: The US, Mexico, and Canada
• Latin America: Brazil and Rest of Latin America
• Middle East & Africa: GCC Countries and Rest of Middle East & Africa

This report aims to provide:

• A qualitative and quantitative analysis of the current trends, dynamics, and estimations.
• The analysis tools such as SWOT analysis, and Porter’s five force analysis are utilized which explain the potency of the buyers and suppliers to make profit-oriented decisions and strengthen their business.
• The in-depth analysis of the market segmentation helps to identify the prevailing market opportunities.
• In the end, this Whole Exome Sequencing report helps to save you time and money by delivering unbiased information under one roof.

About Data Bridge Market Research:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact us:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches